



Sharp L, O'Leary E, O'Ceilleachair A, Skally M, Hanly P. <u>Financial Impact of</u> <u>Colorectal Cancer and Its Consequences: Associations between Cancer-Related</u> <u>Financial Stress and Strain and Health-Related Quality of Life</u>. *Diseases of the Colon and Rectum* 2018, **61**(1), 27-35.

DOI link

https://doi.org/10.1097/DCR.000000000000923

ePrints link

http://eprint.ncl.ac.uk/pub_details2.aspx?pub_id=244705

Date deposited

16/01/2018

Embargo release date

01/01/2019

Copyright

This is a non-final version of an article published in final form in Diseases of the Colon & Rectum. 61(1):27–35, JAN 2018.

The financial impact of colorectal cancer and its consequences: associations between cancer-					
related financial stress and strain and health-related quality-of-life					
Linda Sharp PhD, ^{1*} Eamonn O'Leary MSc, ² Alan O'Ceilleachair MEconSc, ² Mairead Skally MSc, ³ Paul					
Hanly PhD ⁴					
¹ Institute of Health & Society, Newcastle University, England					
² National Cancer Registry Ireland, Cork, Ireland					
³ Beaumont Hospital, Dublin, Ireland					
⁴ National College Ireland, Dublin, Ireland					
Corresponding author: Linda Sharp, Institute of Health & Society, Newcastle University, Baddiley					
Clark Building, Richardson Road, Newcastle-upon-Tyne, England. Tel +44 (0)191 208 6275; fax: +44					
(0)191 208 6043; email: linda.sharp@ncl.ac.uk					
Running title: Financial impact and quality-of-life in colorectal cancer					
Financial Disclosure: This study was funded by a grant from the Health Research Board (SA/2004/1).					
Keywords: colorectal cancer, colon cancer, rectal cancer, health-related quality-of-life, financial					
hardship					
Article word count: 2993					
Abstract word count: 297					
Contributions : <i>Conception/Design:</i> Linda Sharp; <i>Collection and/or assembly of data:</i> Alan					
O'Ceilleachair, Paul Hanly, Linda Sharp; Data analysis: Eamonn O'Leary, Linda Sharp; Interpretation:					
Linda Sharp, Eamonn O'Leary, Alan O'Ceilleachair, Mairead Skally, Paul Hanly; Manuscript writing:					

Linda Sharp, Eamonn O'Leary, Alan O'Ceilleachair, Mairead Skally, Paul Hanly; *Final approval of manuscript:* Linda Sharp, Eamonn O'Leary, Alan O'Ceilleachair, Mairead Skally, Paul Hanly **Category:** colorectal/anal neoplasia

ABSTRACT

Background: The financial impact of cancer on survivors' lives, and its consequences, remain poorly understood. This is especially true for colorectal cancer.

Objective: We investigated objective cancer-related financial stress, subjective cancer-related financial strain and their association with health-related quality-of-life in colorectal cancer survivors. **Design:** Cross-sectional postal survey

Setting: Ireland, which has a mixed public-private healthcare system

Patients: Colorectal cancer survivors, diagnosed 6-37 months previously, were identified from the population-based National Cancer Registry.

Main Outcome Measures: Cancer-related financial stress was assessed as impact of cancer on household ability to make ends meet; and cancer-related financial strain by feelings about household financial situation since cancer diagnosis. Health-related quality-of-life was based on European Organisation for Research and Treatment of Cancer QLQ-C30 global health status. Logistic regression was used to identify associations between financial stress and strain and low healthrelated quality-of-life (lowest quartile, score ≤50).

Results: 493 survivors participated. Overall, 41% reported cancer-related financial stress and 39% cancer-related financial strain; 32% reported both financial stress and financial strain. After adjustment for socio-demographic and clinical variables, the odds of low health-related quality-of-life were significantly higher in those who reported cancer-related financial stress post-diagnosis compared to those who reported no change in financial stress post-cancer (odds ratio=2.54, 95% confidence interval 1.62-3.99). The odds of low health-related quality-of-life were also significantly higher in those strain post-diagnosis (1.73, 1.09-2.72). The odds ratio for those with both cancer-related financial stress and financial strain was 2.59 (1.59-4.22).

Limitations: Survey responders were younger, on average, than non-responders. Responders and non-responders may have differed in cancer-related financial stress and strain or health-related quality-of-life.

Conclusions: Four in ten colorectal cancer survivors reported an adverse financial impact of cancer. Cancer-related financial stress and strain were significantly associated with low health-related quality-of-life. To inform support strategies, further research is needed to better understand how both objective and subjective financial distress influence survivors' health-related quality-of-life.

INTRODUCTION

Population ageing and rising survival mean that more people are living with colorectal cancer. In developed countries, substantial health service-related costs are associated with diagnosis, treatment and follow-up of colorectal cancer.^{1,2} Increasingly, however, there is recognition that additional perspectives on the economic burden of merit consideration, including that of those living with the cancer.

Colorectal cancer patients may incur cancer-related out-of-pocket expenses (e.g. for medical visits or treatment)³⁻⁶ and/or loss of income due to cancer-related work absence,^{7,8} and these have the potential to lead to cancer-related financial hardship. Although the literature on financial hardship among cancer survivors is growing,⁹⁻¹⁴ it has significant limitations. Few studies are specific to colorectal cancer, most come from a few mainly public or mainly private healthcare systems, and very few specify whether the hardship is a result of the cancer diagnosis or simply reflects pre-existing financial difficulties. One study which did focus on the financial impact of the cancer found that 38% of colon cancer patients in the US experienced one or more financial hardships resulting from treatment.¹⁵

A further limitation relates to measurement of cancer-related financial hardship. In assessing the financial impact of illness, both objective and subjective measures of impact should be considered.^{16,17} An objective measure assesses the impact of financial stressors experienced by the household, such as additional costs, while a subjective measure characterises how an individual perceives the financial impact. No colorectal cancer studies (and very few studies of other cancers) have considered these two dimensions of cancer-related financial impact.

Moreover, the wider consequences of cancer-related financial difficulties on colorectal cancer survivors' lives are underreported. Studies in other cancers have indicated that patients who

experience financial hardship, difficulties or distress may have poorer psychological wellbeing, general wellbeing or health-related quality-of-life (HRQoL)¹⁸⁻²¹ but there has been little similar work in colorectal cancer.^{14,22,23}

This study aimed to investigate – for the first time - associations between objective cancer-related financial stress and subjective cancer-related financial strain and HRQoL in colorectal cancer survivors, in a country with a mixed public-private healthcare system.

METHODS

Setting

The study setting was Ireland, which has a complex mixed public-private healthcare system.²⁴ All residents are entitled to care within the public system. Cancer care within the public system has been largely centralised. For colorectal cancer treatment, there are eight designated cancer centres and 85-90% of those who undergo surgery are treated in public hospitals. Unless an individual holds a medical card (eligibility for which is based on financial means and age), they must make modest co-payments for visits to doctors or overnight stays in public hospitals (e.g. approximately €60 to visit a GP) and pay full cost of prescription medications. Approximately half of the population holds private health insurance which, in the main, covers hospital in-patient stays either in a private hospital or as a private patient in a within a public hospital; costs of GP visits, and prescriptions medications, are not usually covered. Individuals may join the Drug Payment Scheme which applies a ceiling - €120 per month - to the amount that they have to pay for prescription drugs and certain aids (including ostomy appliances).

Participants

In January 2010, survivors of primary, invasive colorectal cancer (ICD10 C18-C20) were identified through the National Cancer Registry (NCR). Cancer registration is population-based and

completeness is estimated to be in excess of 97%. Survivors had to be diagnosed between October 2007 and September 2009, believed to be still alive and treated at one of 38 hospitals. Treating clinicians were asked to confirm whether each individual was (i) aware they had cancer; (ii) able to understand English; and (iii) well enough to participate (in particular, cognitively able to give informed consent). Those who were not eligible on this basis, or whose clinician did not respond, were excluded. A questionnaire was sent by post to 1,273 eligible individuals; survivors were between 6 and 37 months from diagnosis at the time they received the questionnaire. Non-responders were sent up to two reminders at fortnightly intervals.

The study was approved by the research ethics committees of the hospitals at which the survivors had been treated. Participants provided written informed consent.

Questionnaire and other data

Health-related quality-of-life

The questionnaire included the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, which has been developed and validated to assess different aspects of HRQoL in patients with a range of cancers from different countries.^{25,26} The final two questions, which ask respondents to rate their health and quality-of-life over the past week on a scale of 1 (very poor) to 7 (excellent), constitute the global health score which can be interpreted as a measure of overall HRQoL. The questions were scored as recommended to generate a single value in the range from 0 (poorest HRQoL) to 100 (best HRQoL).

Cancer-related financial stress and strain

Following Francoeur¹⁶ and previous work on financial hardship among cancer survivors in Ireland,^{20,27} the questionnaire included one objective and one subjective measure of cancer-related financial impact – the former termed cancer-related financial stress and the latter cancer-related financial

strain. Cancer-related financial stress was assessed as the impact of the cancer diagnosis on the household's ability to make ends meet, and cancer-related financial strain as the impact on the individual (i.e. how the respondent had felt about their household's financial situation since their cancer diagnosis). Response options for these questions were 7-level Likert-type scales ranging from "much more difficult"/"very concerned" to "much less difficult"/"much less concerned". These were collapsed for analysis into three groups: more difficult/concerned, no change, and less difficult/concerned. Those who fell into the categories more difficult or more concerned were considered to experience cancer-related financial stress or strain, respectively. For analysis, a third variable (cancer-related financial impact) was created based on the combination of responses to the financial stress and strain questions. This had three categories: both stress and strain, either stress or strain.

Potential confounding variables

Demographic, socio-economic and clinical variables are associated with HRQoL in colorectal cancer.²⁸⁻³⁰ The clinical variables available from the Registry were: site, stage at diagnosis, treatments received (cancer-directed surgery, chemotherapy, radiotherapy, and number of treatments) within a year of diagnosis and time since diagnosis. Presence of a stoma was self-reported on the questionnaire. Demographic variables from the questionnaire were: age at questionnaire completion; marital status; whether the individual lived with others or alone; nationality; sex; and whether the individual had children. Socio-economic variables derived from the questionnaire were: highest level of education completed, employment status at the time of diagnosis, and the identity of the main earner in the household.

Statistical Analysis

Socio-demographic and clinical characteristics of responders and non-responders were compared using chi-square tests. Mean HRQoL scores were compared between cancer-related financial stress,

strain and impact groups using analysis of variance and the magnitude of the differences assessed for clinical significance; following Osoba et al.³¹ differences of 5–9.9, 10–19.9 and \geq 20 points were considered 'minimally', 'moderately' and 'largely' clinically significant, respectively. Regression models were developed to test associations between cancer-related stress and strain and HRQoL. Since the key assumptions underlying linear regression were violated, HRQoL was collapsed into a binomial outcome allowing use of logistic regression. Since there is no pre-defined cut-off for low HRQoL, this was defined *a priori* as the 25% of individuals with the lowest HRQoL scores. To build a multivariable model, relationships between each demographic, socio-economic and clinical variable and HRQoL were evaluated. Variables which were significant (p<0.05) were fitted simultaneously and those which remained significant at this level (and which were not collinear with other variables) were retained in the model. Cancer-related financial stress, cancer-related financial strain, and cancer-related financial impact were added (separately) to this model. The final models had adequate fit. In sensitivity analyses, the final models were re-run using multiple linear regression. All analyses were conducted in Stata 14.0.

RESULTS

Respondents' characteristics and HRQoL

In total, 496 survivors returned questionnaires; responses from three individuals were very incomplete so they were excluded, leaving 493 for analysis (response rate 39%). Responders and non-responders did not differ significantly in terms of sex; cancer site; receipt of surgery, chemotherapy or radiotherapy; stage at diagnosis; or time since diagnosis. They did differ by age (p<0.01); non-responders were, on average, slightly older than responders.

Demographic, socio-economic and clinical characteristics of responders are shown in Table 1. Men accounted for 63% of respondents; almost 40% were aged under 65, 33% were 65-74 and 28% were 75 and older; 38% were within a year of diagnosis, 48% were 1-2 years and 15% were ≥2 years from

diagnosis; 62% had colon cancer; 86% had had cancer-directed surgery; 28% had had chemotherapy; 16% had had radiotherapy; and 22% currently had a stoma.

474 respondents provided information on HRQoL. The mean score was 69.8 (sd 21.6); the median was 66.7 (inter-quartile range 50.0-83.3).

Cancer-related financial stress, strain and impact

464 respondents completed the cancer-related financial stress question. Of these, 41.0% had cancer-related financial stress (i.e. they reported that cancer had made it more difficult for their household to make ends meet); 56.7% reported no change; and 2.4% reported that cancer had made it less difficult to make ends meet (Figure 1).

Information about cancer-related financial strain was provided by 467 respondents. 39.4% had cancer-related financial strain (i.e. they were more concerned about their household's financial situation since their cancer diagnosis); 48.4% reported no change; and 12.2% reported that they were less concerned (Figure 1).

Of the 461 respondents who answered both questions, 32.1% reported both financial stress and strain, 16.7% reported either financial stress or strain, and 51.2% reported neither financial stress nor strain.

Demographic, socio-economic and clinical variables and low HRQoL

Associations between individual demographic, socio-economic and clinical variables and low HRQoL are shown in Supplementary Table 1. Receipt of chemotherapy, presence of a stroma, having children and educational level remained in the multivariate model (Table 2). The odds of low HRQoL were 40% lower in those who had had chemotherapy (adjusted OR=0.59, 95%CI 0.36-0.98)

compared to those who had not, and were 80% higher in those who currently had a stoma (OR=1.80, 95% CI 1.11-2.92) compared to those who did not. Compared to those with a secondary level education, those who had completed only primary education had almost two-fold raised odds of low HRQoL (OR=1.97, 95%CI 1.21-3.19). Having children was also associated with two-fold raised odds (OR=2.18, 95%CI 1.24-3.83).

Mean HRQoL by cancer-related financial stress, strain and impact

Mean HRQoL scores varied significantly by cancer-related financial stress, strain and impact (Supplemental Table 2; all p<0.001). The mean HRQoL among those who reported cancer-related financial stress was 12.9 points lower than among those who reported no change, a moderately clinically significant difference. The difference in mean HRQoL between those reporting financial strain versus no change (9.2 points) was minimally clinically significant. Those who reported both cancer-related financial stress and strain had a moderately clinically significantly higher mean HRQoL than those who reported neither stress nor strain (difference 13.6 points).

Cancer-related financial stress, strain, and impact and low HRQoL

38% of those who reported cancer-related financial stress had low HRQoL, compared to 19% who stated that cancer had had no impact on their household's financial situation, and 10% who reported that their household's financial situation was less difficult since diagnosis (chi-square p<0.001); unadjusted ORs are shown in Supplementary Table 1. After adjusting for educational level, children, current stoma and chemotherapy, there was a significant association between cancer-related financial stress and low HRQoL (likelihood ratio test (LRT) p<0.001). The odds of low HRQoL were significantly higher in those with cancer-related financial stress compared to those reporting no change (OR=2.54, 95%CI 1.62-2.3.99)(Table 3).

Low HRQoL was present in 34% of those reporting cancer-related financial stress, compared to 23% of those who stated that their feeling about their household's financial situation had not changed, and 14% of those who indicated that they were less concerned (chi-square p=0.003). ORs are shown in Supplementary Table 1. After adjustment, there was a significant association between cancer-related financial strain and low HRQoL (LRT p=0.009). Compared to those reporting no change, the odds of low HRQoL were 1.73 times higher (95%Cl 1.09-2.72) in those who experienced cancer-related financial strain (Table 3).

Compared to those with neither cancer-related financial stress nor strain, the multivariable ORs were 1.39 (95%CI 0.73-2.65) for those with either stress or strain and 2.59 (95%CI 1.59-4.99) for those with both (Table 3).

Sensitivity analysis

In the sensitivity analysis using linear regression, all three financial hardship variables were significantly associated with HRQoL after adjusting for socio-demographic and clinical variables; patterns of association were very similar to those from logistic regression (Supplementary Table 3).

DISCUSSION

Prevalence of cancer-related financial hardship

In this study, four in every 10 colorectal cancer survivors reported experiencing either cancer-related financial stress or cancer-related financial strain, and one-third experienced both. It is difficult to compare levels, or prevalence, of cancer-related financial difficulties between studies because authors have used very different questions⁹ which probably measure somewhat different constructs. Despite this, it was noteworthy that prevalence of cancer-related financial impact in our study was similar to prevalence of cancer-related financial hardships in a US study of colon cancer survivors,¹⁵ particularly given that cancer patients in Ireland are entitled to care within the public healthcare

system and, while most patients incur some cancer-related out-of-pocket costs, for the majority these are relatively modest.⁶ This suggests that cancer can have a significant financial impact on colorectal cancer patients in different healthcare systems (and even where there is public provision) and provides further evidence to suggest that financial protections in health are inadequate.³²

Compared to a study breast and prostate cancer survivors in Ireland, which used the same financial impact questions, the prevalence of cancer-related financial stress in the current study was lower (41% vs 48%) and the prevalence of financial strain was higher (39% vs 32%).²⁷ In the breast and prostate cancer study, employment status at diagnosis was an important predictor of financial impact, with risk highest in the group who were working at diagnosis; this was most likely explained by income "shock" i.e. loss of income as a result of time away from work due to cancer. In the current study, the percentage reporting cancer-related financial stress was higher among colorectal cancer survivors working at diagnosis than other groups (employed/self-employed 58%; retired 29%, other 32%) but the proportion of colorectal cancer survivors in paid work at diagnosis was lower than among breast and prostate cancer survivors.^{33,34} This could account for the lower prevalence of cancer-related financial stress in colorectal survivors.

The higher prevalence of financial strain is more difficult to explain. Some colorectal cancer survivors experience ongoing cancer-related costs (e.g. stoma bags, clothes, dietary supplements) and it could be that these recurring costs (albeit modest) serve to remind survivors of financial outlays and stimulate financial concerns. Notably, 50% of those with a stoma at the time of the survey reported cancer-related financial strain compared to 36% of those without a stoma.

In terms of other drivers of cancer-related financial hardship in this population, in *post hoc* analyses we found no association with out-of-pocket costs. However, as we have noted elsewhere,⁶ the magnitude of out-of-pocket costs is partly a function of ability to pay (i.e. those with higher costs are

often those most able to meet these costs). Both private health insurance and access to medical cards appear to provide some protection against cancer-related financial hardship. The prevalence of financial stress was higher in those without private health insurance (46% vs 37%) and the prevalence of both stress and strain was higher in those without a medical card at diagnosis (stress: 47% vs 36%; strain 47% vs 32%), although the high frequency of stress and strain in those without these financial protections indicated that other factors are involved. Beyond this study, although recognition is growing that cancer can cause financial hardship/difficulties/impact,^{10,35-36} relatively little is known about the prevalence or what predisposes cancer survivors to them, especially for specific cancers and outside the US. The current study extends the evidence-base, but further research in these areas is urgently required. In particular, it would be useful to better understand drivers of - and buffers against – cancer-related financial hardship in settings like Ireland where publicly-funded healthcare is available.

Cancer-related financial stress and strain and HRQoL

Cancer-related financial stress and strain, and the combination of these, were associated with low HRQoL after adjusting for socio-demographic and clinical factors. Moreover, the difference in mean HRQoL scores between those who reported cancer-related financial stress or strain and those who did not attained clinical significance.

Studies in other cancers have reported associations between financial burden and poorer psychological wellbeing.^{18,20} From qualitative research, we have previously postulated inter-play between the financial and emotional impacts of colorectal cancer such that financial distress may exacerbate emotional distress.³⁷ This is compatible with research in the population which indicates that poverty imposes a cognitive load and consumes mental resources.³⁸ Others have reported associations between poorer psychological wellbeing and lower HRQoL in colorectal cancer.³⁹ This suggests that our findings could be indirectly due to the financial impact adversely affecting

emotional wellbeing. A recent study observed that colorectal cancer patients with limited financial reserves (i.e. savings) 4-months post-diagnosis had a significantly higher symptom burden⁴⁰ and, since symptoms are strong predictors of HRQoL, this provides another possible explanation. Future studies should seek to test whether cancer-related financial distress affects HRQoL by influencing psychological wellbeing, symptom burden, or though some other route. There is also a need to understand the (potentially different) pathways underlying development of objective and subjective cancer-related financial distress; it is possible that distinct interventions or supports may be needed to alleviate these different dimensions of the financial impact of cancer.

Practice Implications

The relationship between financial impact of cancer and low HRQoL means healthcare professionals should be alert to the possibility of financial distress (objective or subjective) among survivors, and seek to identify this at an early stage. From a policy- and decision-maker perspective, the development of strategies or supports to alleviate the (objective or subjective) financial impact of colorectal cancer could lead to improved HRQoL.

Strengths & Limitations

Although study participants were identified from a population-based sampling frame, the response rate was only 39%. It was reassuring, therefore, that the socio-demographic and clinical characteristics of respondents and non-respondents differed only in age and age was not a significant predictor of HRQoL. Some people who returned the questionnaire did not complete the HRQoL questions or the questions on cancer-related financial stress and strain; although numbers were small, those who did not complete these sections tended to be older on average than those who did. We cannot exclude the possibility that those who completed all of the questions, those who completed some, and non-respondents differed in cancer-related financial stress or strain or HRQoL. The questions on cancer-related financial stress and strain had been used in previous studies

and showed good convergent validity with other markers of the financial burden of cancer in survivors in Ireland.²⁰ They were designed to investigate objective and subjective aspects of the financial impact of cancer¹⁶ and – as far as we are aware - this is the first study of these two dimensions of financial burden in colorectal cancer survivors. However, we acknowledge that both questions are somewhat subjective in nature in that they ask about respondents' own views of the financial impact of cancer on their household and self. In addition, we lacked information on comorbid conditions, and it is possible that (although the questions asked about the impact of the cancer) for some survivors the financial hardship may result from presence of other conditions. Moreover, we note that the data was collected some time ago (notably, before the full impact of the economic crisis in Ireland). It is therefore unclear whether current frequencies of financial stress and strain would be the same as reported here. Finally, in common with other studies on this topic, it cannot be assumed that the prevalence of financial hardship (irrespective of how measured) in Ireland is representative of experiences in other countries.

Because assumptions underlying linear regression were violated we used logistic regression for our primary analysis. A lack of a generally-recognised threshold for low HRQoL (as measured using the global health score from the EORTC QLQ-C30) led us to define this *a priori* as the lowest quantile, but whether this corresponds to clinical importance is unknown. Thresholds for clinical importance have recently been published for several other EORTC QLQ-C30 subscales;⁴¹ a similar thresholds for the global health score would be of considerable value.

Conclusions

In this first study to distinguish between objective and subjective measures of cancer-related financial impact in colorectal cancer, four in every 10 survivors reported objective cancer-related financial stress, four in 10 reported subjective cancer-related financial strain, and one-third reported both. Survivors experiencing cancer-related financial stress and/or strain had significantly increased

odds of low health-related quality-of-life, and the differences in HRQoL between those with and without financial stress or strain were clinically significant. Further research is needed to better understand the routes by which financial distress affects HRQoL among cancer survivors. Meantime, greater recognition of the (objective and subjective) financial impact of cancer on survivors and their families, and the development of strategies to alleviate this, could yield HRQoL benefits.

ACKNOWLEDGEMENTS

The authors are grateful to: the staff at the National Cancer Registry who collect and process the data on the cancer patients; the clinicians and their teams who reviewed patients' details for eligibility; the survivors who participated in the study; and Dr Aileen Timmons for involvement in developing the cancer-related financial stress and strain questions.

REFERENCES

- 1. O'Céilleachair A, Hanly P, Skally M, et al. Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer. *Medical Care*. 2013;51:339-350.
- 2. Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncol.* 2013;14:1165-1174.
- 3. Longo CJ, Deber R, Fitch M, et al. An examination of cancer patients' monthly 'out-of-pocket' costs in Ontario, Canada. *Eur J Cancer Care.* 2007;16:500-507.
- 4. Guy GP, Ekwueme DU, Yabroff KR, et al. Economic burden of cancer survivorship among adults in the United States. *J Clin Oncol.* 2013;31:3749-3757.
- 5. Marti J, Hall PS, Hamilton P, et al. The economic burden of cancer in the UK: a study of survivors treated with curative intent. *Psycho-Oncol.* 2016;25:77-83.
- O'Ceilleachair A, Hanly P, Skally M, O'Leary E, O'Neill C, Fitzpatrick P, Kapur K, Staines A, Sharp L. Counting the cost of cancer: out-of-pocket payments made by colorectal cancer survivors. Supportive Care Cancer (under review).
- 7. Bhalla A, Williams JP, Hurst NG, et al. One-third of patients fail to return to work 1 year after surgery for colorectal cancer. *Tech Colonproctol.* 2014;18:1153-1159.
- Gordon LG, Beesley VL, Lynch BM, et al. The return to work experiences of middle-aged Australian workers diagnosed with colorectal cancer: a matched cohort study. *BMC Pub Health*. 2014;14:963.
- 9. Azzani M, Roslani AC, Su TT. The perceived cancer-related financial hardship among patients and their families: a systematic review. *Support Care Cancer*. 2015;23:889-898.
- 10. McNulty J, Khera N. Financial Hardship—an Unwanted Consequence of Cancer Treatment. *Curr Hematol Malig Rep.* 2015;10:205-212.
- 11. Arndt V, Merx H, Stegmaier C, et al. Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: a population based study. *Eur J Cancer*. 2006;42:1848-1857.
- Verhaar S, Vissers PAJ, Maas H, et al. Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: Results from the populationbased PROFILES registry. *Eur J Cancer* 2015;51:1263-1273.
- 13. Wright P, Downing A, Morris EJ, et al. Identifying social distress: a cross-sectional survey of social outcomes 12 to 36 months after colorectal cancer diagnosis. *J Clin Oncol.* 2015;33:3423-3430.
- 14. Zafar SY, McNeil RB, Thomas CM, et al. Population-based assessment of cancer survivors' financial burden and quality of life: A prospective cohort study. *J Oncol Pract.* 2015;11:145-150.

- Shankaran V, Jolly S, Blough D, et al. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. *J Clin Oncol.* 2012;30:1608-1614.
- 16. Francoeur RB. Cumulative financial stress and strain in palliative radiation outpatients: The role of age and disability. *Acta Oncol.* 2005;44: 369-381.
- 17. Valtorta NK, Hanratty B. Socioeconomic variation in the financial consequences of ill health for older people with chronic diseases: a systematic review. *Maturitas.* 2013;74:313-333.
- 18. Baider L, Andritsch E, Uziely B, et al. Do different cultural settings affect the psychological distress of women with breast cancer? A randomized study. *Eur J Cancer Care.* 2003;12:263-273.
- 19. Gupta D, Lis CG, Grutsch JF. Perceived cancer-related financial difficulty: implications for patient satisfaction with quality of life in advanced cancer. *Supportive Care Cancer*. 2007;15:1051-1056.
- 20. Sharp L, Carsin AE, Timmons A. Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer. *Psycho-Oncol.* 2013;22:745-755.
- Delgado-Guay M, Ferrer J, Rieber AG, et al. Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. *Oncologist.* 2015;20:1092-1098.
- 22. Färkkilä N, Sintonen H, Saarto T, et al. Health-related quality of life in colorectal cancer. *Colorectal Dis.* 2013;15:e215-e22.
- 23. Kinoshita Y, Chishaki A, Kawamoto R, et al. A longitudinal study of gender differences in quality of life among Japanese patients with lower rectal cancer treated with sphincter-saving surgery: a 1-year follow-up. *World J Surg Oncol.* 2015;13:91.
- 24. Smith S, Normand C. Equity in health care: the Irish perspective. *Health Econ Policy Law.* 2011;6:205-217.
- 25. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
- 26. Groenvold M, Klee MC, Sprangers MAG, et al. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. *J Clin Epidemiol.* 1997;50:441-450.
- 27. Sharp L, Timmons A. Pre-diagnosis employment status and financial circumstances predict cancer-related financial stress and strain among breast and prostate cancer survivors. *Supportive Care Cancer*. 2015:1-11.

- 28. Dunn J, Lynch B, Aitken J, et al. Quality of life and colorectal cancer: a review. *Aust N Z J Pub Health.* 2003;27:41-53.
- 29. Bloom JR, Petersen DM, Kang SH. Multi-dimensional quality of life among long-term (5+ years) adult cancer survivors. *Psycho-Oncol. 2007*;16:691-706.
- 30. Jansen L, Koch L, Brenner H, et al. Quality of life among long-term (≥ 5years) colorectal cancer survivors–systematic review. *Eur J Cancer.* 2010;46:2879-2888.
- 31. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol.* 1998;16:139–144
- 32. Moreno-Serra R, Millett C, Smith PC. Towards improved measurement of financial protection in health. *PLoS Med.* 2011;8:1166.
- 33. Sharp L, Timmons A. Social welfare and legal constraints associated with work among breast and prostate cancer survivors: experiences from Ireland. *J Cancer Surviv.* 2011;5:382-394.
- 34. Hanly P, Walsh PM, Céilleachair AÓ, et al. Work-related productivity losses in an era of ageing populations: the case of colorectal cancer. *J Occ Env Med.* 2013;55:128-134.
- 35. Bradley CJ. Financial hardship: a consequence of survivorship? J Clin Oncol. 2012;30:1579-1580.
- 36. Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. *Oncology*.2013;27:80-81.
- O'Céilleachair A, Costello L, Finn C, et al. Inter-relationships between the economic and emotional consequences of colorectal cancer for patients and their families: a qualitative study. *BMC Gastroenterol.* 2012;12:62.
- Mani A, Mullainathan S, Shafir E, Zhao J. Poverty impedes cognitive function. *Science*.
 2013;341:976-980
- 39. Gray NM, Hall SJ, Browne S, et al. Modifiable and fixed factors predicting quality of life in people with colorectal cancer. *Br J Cancer.* 2011;104:1697-1703.
- 40. Lathan CS, Cronin A, Tucker-Seeley R, Zafar SY, Ayanian JZ, Schrag D. Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. *J Clin Oncol.* 2016;34:1732-1740.
- 41. Giesinger JM, Kuijpers W, Young T, et al. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. *Health Qual Life Outcomes.* 2016;14:87.

Figure Legends

Figure 1: Distribution of cancer-related financial stress and strain among colorectal cancer survivors

	Number	%
Total	493	100.0
Demographic variables		
Sex		
Male	310	62.9
Female	183	37.1
Age at time of questionnaire completion		
<65	194	39.4
65-74	163	33.1
75+	136	27.6
Marital status at diagnosis		
Married/cohabiting	373	75.8
Other	119	24.2
Not reported	1	
Living alone at time of diagnosis		
No	409	83.5
Yes	81	16.5
Not reported	3	
Children		
Yes	420	86.2
No	67	13.8
Not reported	6	
Nationality		
Irish	467	94.9
Other	25	5.1
Not reported	1	
Socio-economic variables		
Highest level of education completed		
Primary	146	29.9
Secondary	236	48.3
Tertiary	107	21.9
Not reported	4	
Employment status at diagnosis		
Employed/self-employed	188	38.9
Retired	203	42.0
Other	92	19.1
Not reported	10	

Table 1. Characteristics of colorectal cancer survivors included in analysis. Numbers and percentages.

Main earner in household		
Survivor	300	62.6
Spouse/other	118	24.6
Shared between survivor/spouse	61	12.7
Not reported	14	
Private health insurance at diagnosis		
No	239	48.5
Yes	254	51.5
Medical card at diagnosis ¹		
Yes	241	48.9
No	252	51.1
Clinical variables		
Time since diagnosis		
<1 year	185	37.5
1-2 years	234	47.5
>2 years	74	15.0
Site		
colon	305	61.9
rectum	188	38.1
Stage at diagnosis		
Stage 1	91	18.5
Stage 2	141	28.6
Stage 3	175	35.5
Stage 4	36	7.3
Not known/ not staged	50	10.1
Cancer-directed surgery		
Yes	425	86.2
No	68	13.8
Chemotherapy		
Yes	138	28.0
No	355	72.0
Radiotherapy		
Yes	80	16.2
No	413	83.8
Number of treatments received		
None	44	8.9
1	286	58
2	132	26.8
3	31	6.3

Currently has a stoma		
Yes	105	21.3
No	388	78.7
¹ eligibility based on financial means and age; provides access	s to healthcare in public sy	vstem, GPs, and

prescription medications free at the point of delivery

<u> </u>	Number	%	AdjOR	95% CI	p
Children					
Yes	98	24.2	1.00	-	0.008
No	26	40.0	2.18	1.24-3.83	
Highest level of education completed	d				
Primary	47	34.0	1.97	1.21-3.19	0.021
Secondary	51	22.1	1.00	-	
Tertiary	26	24.8	1.17	0.67-2.04	
Chemotherapy					
No	98	28.6	1.00	-	0.037
Yes	26	19.9	0.59	0.36-0.98	
Current stoma					
No	87	23.4	1.00	-	0.019
Yes	37	36.3	1.80	1.11-2.92	

Table 2. Associations between significant demographic, socio-economic and clinical variables and low HRQoL: numbers and % with low HRQoL, adjusted odds ratios (AdjOR)¹ with 95% confidence intervals (CI), and p values from likelihood ratio tests

¹ mutually adjusted for the variables shown in the table

Table 3. Associations between cancer-related financial impact and low HRQoL, adjusted for demographic, socio-economic and clinical variables: numbers and % with low HRQoL, adjusted odds ratios (AdjOR)¹ with 95% confidence intervals (CI), and p values from likelihood ratio tests

	Number	%	AdjOR	95% CI	p
Cancer-related financial stress ²					
financial stress better since diagnosis	1	10.0	0.45	0.06-3.71	<0.001
no change	48	18.8	1.00	-	
financial stress worse since diagnosis	71	37.8	2.54	1.62-3.99	
Cancer-related financial strain ³					
financial strain better since diagnosis	8	14.0	0.61	0.26-1.39	0.009
no change	50	22.8	1.00	-	
financial strain worse since diagnosis	62	34.3	1.73	1.09-2.72	
Cancer-related financial impact					
neither stress nor strain worse	44	19.2	1.00	-	< 0.001 ⁴
either stress or strain worse	18	23.7	1.39	0.73-2.65	
both stress and strain worse	57	39.0	2.59	1.59-4.22	

¹ adjusted for having children, highest level of education completed, receipt of chemotherapy and current stoma

² impact of cancer diagnosis on household's ability to make ends meet

³ feelings about household financial situation since cancer diagnosis

······································	Number	%	OR	95%CI	p
Demographic variables		-	-		
Sex					
Male	77	25.7	1	-	0.749
Female	47	27.0	1.07	0.70-1.64	
Age at time of questionnaire completion					
<65	43	22.6	1	-	0.324
65-74	44	27.5	1.30	0.80 - 2.11	
75+	37	29.8	1.45	0.87 - 2.43	
Marital status at diagnosis					
Married/cohabiting	90	25.1	1	-	0.414
Other	34	29.1	1.21	0.76-1.93	
Living alone at diagnosis					
No	100	25.5	1	-	0.502
Yes	23	29.1	1.20	0.70 - 2.06	
Children					
Yes	98	24.2	1	-	0.010
No	26	40.0	2.09	1.21-3.60	
Nationality					
Irish	116	25.8	1	-	0.423
Other	8	33.3	1.44	0.60-3.45	
Socio-economic variables					
Highest level of education completed					
Primary	47	34.0	1.82	1.14-2.92	0.041
Secondary	51	22.1	1	-	
Tertiary	26	24.8	1.16	0.68-2.00	
Employment status at diagnosis					
Employed/self-employed	43	23.4	1	-	0.447
Retired	57	29.1	1.34	0.85-2.13	
Other	22	25.9	1.15	0.63-2.07	
Main earner in household					
Survivor	85	29.1	1	-	0.179
Spouse/other	24	21.1	0.65	0.39 - 1.09	
Shared between survivor/spouse	13	22.0	0.69	0.35-1.34	
Private health insurance at diagosis					
No	62	25.9	1	-	
Yes	62	24.1	0.92	0.61-1.38	0.695
Medical card at diagnosis					
No	55	22.8	1	-	
Yes	69	27.4	1.27	0.83-1.92	0.243

Supplementary Table 1: Univariate associations between variables and low HRQoL. Numbers and percentages with low HRQoL, odds ratios (OR), 95% confidence intervals (OR) and p values from likelihood ratio tests

Time since diagnosis 44 24.7 0.87 0.56-1.37 0.831 -2 years 19 26.0 0.93 0.51-1.70 Site	Clinical variables					
44 247 0.87 0.51.37 0.831 1.2 years 19 26.0 0.93 0.51.1.70 Site - - 0.059 Colon 67 23.0 1 - 0.059 Retum 57 31.0 1.49 0.99-2.26 0.059 Stage at diagnosis - - 0.059 0.451.30 0.718 Stage 1 22 25.0 0.85 0.451.30 0.718 Stage 2 31 2.0 0.76 0.321.78 0.451.30 Stage 3 47 2.81 1 - - Not known/ not staged 16 32.0 1.20 0.76 0.321.78 No 110 26.9 1.34 0.71-2.52 0.353 Chemotherapy - - 0.049 - 0.49 Yes 26 1.9 0.62 0.38-1.01 - 0.40 Yes 26 1.9 0.62 0.38-1.01 - 0.40 - 2.3 1.4 0.63 0.29-1.37 <td>Time since diagnosis</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Time since diagnosis					
1.2 years 61 27.4 1 - >2 years 19 26.0 0.93 0.51.70 Site 67 23.0 1 - 0.059 Return 57 31.0 1.49 0.99-2.26 0.059 Stage at diagnosis 31 23.1 0.77 0.45-1.30 0.718 Stage 2 31 23.1 0.77 0.45-1.30 0.718 Stage 3 47 28.1 1 - 1.40 0.45-1.30 Stage 4 8 22.9 0.76 0.32-1.78 0.61-2.38 Concer-directed surgery 7 8.1 - - Nofe 10 26.9 1.34 0.71-2.52 0.353 Chemotherapy No 110 26.9 1.34 0.71-2.52 0.353 No 106 25.7 1 - 0.049 748 1.8 2.4 0.84 0.47-1.48 0.540 Yes 26 19.9 0.62 0.38 - 1.01 0.540 748 3.1 - 2.3 1.4	<1 year	44	24.7	0.87	0.56-1.37	0.831
>2 years 19 26.0 0.93 0.51-1.70 Sire 57 23.0 1 - 0.059 Retum 57 31.0 1.49 0.99 - 2.26 0.059 Stage at diagnosis 22 25.0 0.88 0.47-1.53 0.718 Stage 1 23 1 - 0.51-1.30 0.718 Stage 2 31 0.77 0.45-1.30 0.321.78 0.321.78 Not known/ not staged 16 2.29 0.76 0.321.78 0.712.20 0.512.38 Concer-directed surgery Yes 14 21.5 1 - No No 100 269 1.34 0.71-2.52 0.353 Chemotherapy 9 8 2.6 1 - 0.049 Yes 26 19.9 0.62 0.38-1.01 0.49 Wos 16 2.6.7 1 - 0.540 Yes 18 2.3.4 0.84 0.47-1.48 0.510 None 9 2.1.4 0.63 0.29-1.37	1-2 years	61	27.4	1	-	
Site Colon 67 23.0 1 99 - 2.6 0.059 Rectum 57 21.0 1.49 0.99 - 2.6 0.059 Stage 1 22 25.0 0.85 0.47-1.53 0.718 Stage 2 31 23.1 0.77 0.45-1.30 0.718 Stage 3 47 28.1 1 - - Stage 4 8 22.9 0.76 0.32-1.78 0.612-38 Not known/ not staged 16 32.0 1.20 0.61-2.38 0.77 0.61-2.38 Concer directed surgery Wes 14 21.5 1 - - 0.049 Yes 26 19.9 0.62 0.38 - 101 0.049 Yes 26 19.9 0.62 0.38 - 101 0.049 Yes 28 27 1.4 0.7 0.049 Yes 18 23.4 0.84 0.47 - 1.48 0.540 Yes 18 23.4 0.84 0.47 - 1.48 0.540 No 20 18 0.31<	>2 years	19	26.0	0.93	0.51-1.70	
Colon 67 23.0 1 - 0.059 Rectum 57 31.0 1.49 0.99 - 2.26 Stage at diagnosis - 22 25.0 0.85 0.47 - 1.53 0.718 Stage 1 22 25.0 0.85 0.47 - 1.53 0.718 - Stage 3 47 28.1 1 - - - Stage 4 8 22.9 0.76 0.32 - 1.78 - Not known/ not staged 16 32.0 1.20 0.61 - 2.38 - Concer-directed surgery - - - 0.49 Yes 10 26.9 1.34 0.71 - 2.52 0.353 Chematherapy - - 0.49 - - 0.49 Yes 26 19 0.62 0.38 - 1.01 - - 0.49 Yes 18 23.4 0.48 0.47 - 1.48 0.47 - 0.540 Yes 18 23.4 0.48 0.47 - 1.48 0.44 - - - -	Site					
Rectum 57 31.0 1.49 0.99 - 2.26 Stage at diagnosis	Colon	67	23.0	1	-	0.059
Stage at diagnosis Stage 1 22 25.0 0.87 0.47-1.53 0.718 Stage 1 31 23.1 0.77 0.45-1.30 0.32 Stage 3 47 28.1 1 - - Stage 4 8 22.9 0.76 0.32-1.78 0.61-2.38 Cancer-directed surgery 14 21.5 1 - - No 110 26.9 1.34 0.71-2.52 0.353 Chemotherapy No 26 19.9 0.62 0.38 - 10.1 No 106 26.7 1 - 0.049 Yes 26 19.9 0.62 0.38 - 10.1 No 18 23.4 0.84 0.47 - 1.48 Number of treatments received None 9 21.4 0.63 0.29 - 1.37 0.068 No 1 0.47 0.44 0.36 - 1.95 0.011 3 - 2 23 18.4 0.52 0.310.87 0.0011 None 9 21.4 0.63 0.29 - 1.37 0.06	Rectum	57	31.0	1.49	0.99 - 2.26	
Stage 1 22 25.0 0.48 $0.471.53$ 0.718 Stage 2 31 23.1 0.77 $0.451.30$ 0.75 $0.321.78$ Not known/ not staged 16 32.0 1.20 $0.61-2.38$ 0.76 $0.321.78$ Cancer-directed surgery 310 22.9 0.76 $0.321.78$ 0.333 Chemotherapy 14 21.5 1 $ 0.049$ No 100 26.9 1.34 $0.71-2.52$ 0.353 Chemotherapy N_0 98 28.6 1 $ 0.049$ Yes 26 19.9 0.62 $0.38 - 1.01$ 0.49 Radiatherapy N_0 98 28.6 1 $ 0.63$ None 9 21.4 0.63 $0.29 + 1.37$ 0.68 1 2 23 18.4 0.52 $0.31 + 0.52$ $0.31 + 0.52$ None 9 21.4 0.63 $0.29 + 1.37$ 0.068 1 $ 0.011$	Stage at diagnosis					
Stage 2 31 23.1 0.77 0.451.30 Stage 3 47 28.1 1 - Not known/ not staged 16 32.0 1.20 0.61-2.38 Cancer-directed surgery * - - - Yes 14 21.5 1 - - No 100 26.9 1.34 0.71-2.52 0.353 Chemotherapy * 26 19.9 0.62 0.38 + 1.01 No 26 19.9 0.62 0.38 + 1.01 0.49 Yes 26 19.9 0.62 0.38 + 1.01 0.540 No 106 26.7 1 - 0.540 Yes 18 23.4 0.84 0.47 + 1.48 0.52 None 9 21.4 0.63 0.29 + 1.37 0.068 1 2 23 18.4 0.52 0.31 + 0.85 Currently has a stoma * 26 1.0 - 0.011 No 37 36.3 1.86 1.1 - 2 0.01	Stage 1	22	25.0	0.85	0.47-1.53	0.718
Stage 34728.11.Stage 4822.90.760.32-1.78Not known/ not staged1632.01.200.61-2.38Cancer-directed surgeryYes1421.51.Yes11026.91.340.71-2.520.353ChemotherapyNo9828.61.0.049Yes2619.90.620.381.010.49Yes2619.90.620.381.010.49No9828.61.0.0490.63Yes2619.90.620.381.010.540No10626.71.0.540Yes1823.40.840.47-1.480.540None921.40.630.29-1.370.06812310.540Yes1825.70.840.361.1950.5122318.40.520.31-0.870.01133826.70.840.361.195Currently has a stoma7736.31.861.17-2.980.011No3736.31.861.17-2.980.001No1000.480.06-3.87<0.001	Stage 2	31	23.1	0.77	0.45-1.30	
Stage 4822.90.760.32-1.78Not known/ not staged1632.01.200.61-2.38Cancer-directed surgery*1421.51-Yes1421.51.340.71-2.520.353Chemotherapy9828.61-0.049No9828.61-0.049Yes2619.90.620.38 - 1.010.49Ves2619.90.620.38 - 1.010.49No10626.71-0.540Yes10626.71-0.540Number of treatments received921.40.630.29 - 1.370.068None921.40.630.29 - 1.370.068122318.40.520.31 - 630.2922318.40.520.31 - 630.290.54None921.40.630.29 - 1.370.068122318.40.520.31 - 630.01No3736.31.861.17 - 2.980.011No3736.31.861.17 - 2.980.001No3736.31.861.17 - 2.980.001No3736.31.861.17 - 2.980.001No3736.31.861.17 - 2.980.001No373736.31.661.17 - 2.930.001No3	Stage 3	47	28.1	1	-	
Not known/ not staged 16 32.0 1.20 0.61-2.38 Cancer-directed surgery Yes 14 21.5 1 - No 110 26.9 1.34 0.71-2.52 0.353 Chemotherapy 98 28.6 1 - 0.049 No 98 28.6 1 - 0.049 Yes 26 1.9 0.62 0.38-1.01 0.540 Radiotherapy 98 28.6 1 - 0.049 No 98 28.7 1 - 0.049 Yes 18 23.4 0.84 0.47-1.48 0.540 Number of treatments received 84 30.3 1 - 0.068 1 2 23 18.4 0.52 0.31-0.87 0.068 1 84 30.3 1.86 1.17-2.98 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial inpact variables 1 1.00 0.48 0.06-3.87 0.001 fin	Stage 4	8	22.9	0.76	0.32-1.78	
Cancer-directed surgery Yes 14 21.5 1 - No 110 26.9 1.34 0.71-2.52 0.353 Chemotherapy No 98 28.6 1.9 0.62 0.38-1.01 Radiotherapy 98 28.6 1.9 0.62 0.38-1.01 No 98 28.7 1 - 0.049 Radiotherapy 18 23.4 0.84 0.47-1.48 Number of treatments received 9 21.4 0.63 0.29-1.37 0.068 1 84 30.3 1 - 2 0.013 - 2 23 18.4 0.52 0.31-0.87 - 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables 1 1.00 0.48 0.06-3.87 <0.001	Not known/ not staged	16	32.0	1.20	0.61-2.38	
Yes1421.51-No11026.91.340.71-2.520.353ChemotherapyNo9828.61-0.049Yes2619.90.620.38 - 1.010.49Radiotherapy026.71-0.540No10626.71-0.540Yes1823.40.630.29 - 1.370.0681231.840.520.31 - 0.8722318.40.520.31 - 0.870.068122318.40.520.31 - 0.873826.70.840.36 - 1.950.011Currently has a stomaYes8723.41-No3736.31.861.17 - 2.980.011Financial impact variablesCancer-related financial stress 1financial stress better since diagnosis110.00.480.06 - 3.87<0.001	Cancer-directed surgery					
No 110 26.9 1.34 0.71-2.52 0.353 Chemotherapy No 98 28.6 1 - 0.049 Yes 26 19.9 0.62 0.38 - 1.01 0.049 Radiotherapy No 106 26.7 1 - 0.540 Yes 18 23.4 0.84 0.47 - 1.48 0.540 Number of treatments received None 9 21.4 0.63 0.29 - 1.37 0.068 1 23 18.4 0.52 0.31 - 0.540 0.463 0.47 - 1.48 0.68 1 23 18.4 0.52 0.31 - 0.540 0.68 0.47 - 1.48 0.68 1 2 3 8 26.7 0.84 0.36 - 1.95 0.011 Currently has a stoma Yes 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17 - 2.98 0.001 Financial impact variables 1 1.00 0.48 0.06 - 3.87 <0	Yes	14	21.5	1	-	
Chemotherapy No 98 28.6 1 - 0.049 Yes 26 19.9 0.62 0.38 - 1.01 0.049 Radiatherapy No 106 26.7 1 - 0.540 Number of treatments received None 9 21.4 0.63 0.29 - 1.37 0.068 1 84 30.3 1 - - 0.62 0.31 - 0.540 2 23 18.4 0.52 0.31 - 0.540 0.63 0.29 - 1.37 0.068 1 2 0.33 1 - - 0.540 0.52 0.31 - 0.57 0.068 2 3 18.4 0.52 0.31 - 0.87 0.068 0.65 - 0.87 0.011 3 8 26.7 0.84 0.36 - 1.95 0.011 0.48 0.06 - 3.87 0.001 No 37 36.3 1.86 1.17 - 2.98 0.001 0.69 0.011 0.48 0.06 - 3.87 <0.001	No	110	26.9	1.34	0.71-2.52	0.353
No 98 28.6 1 - 0.049 Yes 26 19.9 0.62 0.38 - 1.01 0.62 Radiotherapy No 106 26.7 1 - 0.540 Yes 18 23.4 0.84 0.47 - 1.48 0.63 0.29 + 1.37 0.068 None 9 21.4 0.63 0.29 + 1.37 0.068 1 1 23 18.4 0.52 0.31 - 0.87 0.061 1 2 3 18.4 0.52 0.31 - 0.87 0.011 1 0.061 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - 0.011 1 - <t< td=""><td>Chemotherapy</td><td></td><td></td><td></td><td></td><td></td></t<>	Chemotherapy					
Yes 26 19.9 0.62 0.38 - 1.01 Radiotherapy No 106 26.7 1 - 0.540 Yes 18 23.4 0.84 0.47 - 1.48 0.540 Number of treatments received 9 21.4 0.63 0.29 - 1.37 0.068 1 23 18.4 0.52 0.31 - 0.77 0.068 1 24 30.3 1 - 0.011 2 3 18.4 0.52 0.31 - 0.87 0.011 3 26.7 0.84 0.36 - 1.95 0.011 Currently has a stoma Yes 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17 - 2.98 0.011 Financial impact variables 2 1 - 0.011 Cancer-related financial stress 1 1 0.0 0.48 0.06 - 3.87 <0.001 no change 1 1.00 0.48 0.06 - 3.87 <0.001 no change 50 22.8 1 - <0.001 financial	No	98	28.6	1	-	0.049
RadiotherapyNo10626.71-0.540Yes1823.40.840.47 - 1.480.630.29 - 1.370.068Number of treatments received921.40.630.29 - 1.370.068None921.40.630.29 - 1.370.06818430.3122318.40.520.31 - 0.873826.70.840.36 - 1.95-Currently has a stomaYes8723.41-No3736.31.861.17 - 2.980.011No3736.31.861.17 - 2.980.011Financial impact variablesCancer-related financial stress ¹ financial stress better since diagnosis110.00.480.06 - 3.87<0.001	Yes	26	19.9	0.62	0.38 - 1.01	
No10626.71-0.540Yes1823.40.840.47 - 1.480.47 - 1.48Number of treatments received921.40.630.29 - 1.370.06818430.31218.40.520.31 - 0.840.36 - 1.950.0683826.70.840.36 - 1.950.011Currently has a stomaYes8723.41-0.011No3736.31.861.17 - 2.980.011No colspan="4">Cancer-related financial stress ¹ financial stress better since diagnosis110.00.480.06 - 3.87<0.001	Radiotherapy					
Yes 18 23.4 0.84 0.47 - 1.48 Number of treatments received 9 21.4 0.63 0.29 - 1.37 0.068 1 84 30.3 1 - - 2 23 18.4 0.52 0.31 - 0.87 3 8 26.7 0.84 0.36 - 1.95 Currently has a stoma 8 26.7 0.84 0.36 - 1.95 Yes 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables 7 23.4 1 - 0.011 Cancer-related financial stress ¹ 10.0 0.48 0.66-3.87 <0.001	No	106	26.7	1	-	0.540
Number of treatments received 9 21.4 0.63 0.29-1.37 0.068 1 84 30.3 1 - 2 23 18.4 0.52 0.31-0.87 3 8 26.7 0.84 0.36-1.95 Currently has a stoma Yes 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables Cancer-related financial stress ¹ financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001	Yes	18	23.4	0.84	0.47 - 1.48	
None 9 21.4 0.63 0.29-1.37 0.068 1 84 30.3 1 - 2 23 18.4 0.52 0.31-0.87 3 8 26.7 0.84 0.36-1.95 Currently has a stoma 8 26.7 0.84 0.36-1.95 Yes 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables Zancer-related financial stress ¹ - 0.011 Cancer-related financial stress ¹ - - 0.011 financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001 no change 48 18.8 1 - - <0.001 financial stress worse since diagnosis 71 37.8 2.61 1.70-4.03 Cancer-related financial strain ² 6 22.8 1 - financial strain better since diagnosis 62 34.3 1.76 1.13-2.73 <t< td=""><td>Number of treatments received</td><td></td><td></td><td></td><td></td><td></td></t<>	Number of treatments received					
1 84 30.3 1 - 2 23 18.4 0.52 0.31-0.87 3 8 26.7 0.84 0.36-1.95 Currently has a stoma Yes 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables Cancer-related financial stress ¹ financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001	None	9	21.4	0.63	0.29-1.37	0.068
2 23 18.4 0.52 0.31-0.87 3 8 26.7 0.84 0.36-1.95 Currently has a stoma Yes 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables Cancer-related financial stress ¹ financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001	1	84	30.3	1	-	
3 8 26.7 0.84 0.36-1.95 Currently has a stoma 7 23.4 1 - 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables 1 10.0 0.48 0.06-3.87 <0.001	2	23	18.4	0.52	0.31-0.87	
Currently has a stoma 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17-2.98 0.011 Financial impact variables 50 23.4 1 - 0.011 Financial impact variables 50 0.011 0.011 0.011 0.011 Financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001	3	8	26.7	0.84	0.36-1.95	
Yes 87 23.4 1 - 0.011 No 37 36.3 1.86 1.17-2.98 Financial impact variables - - - 0.011 Cancer-related financial stress ¹ - - - - financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001 no change 48 18.8 1 - - - - financial stress worse since diagnosis 71 37.8 2.61 1.70-4.03 - Cancer-related financial strain ² - - - - - financial strain better since diagnosis 8 14.0 0.55 0.25-1.24 0.003 no change 50 22.8 1 - - - financial strain worse since diagnosis 8 14.0 0.55 0.25-1.24 0.003 no change 50 22.8 1 - - - financial strain worse since diagnosis 8 14.0 0.55 0.25-1.24 0.003	Currently has a stoma					
No 37 36.3 1.86 1.17-2.98 Financial impact variables 2 2 0.06-3.87 <0.001	Yes	87	23.4	1	-	0.011
Financial impact variables Cancer-related financial stress ¹ financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001	No	37	36.3	1.86	1.17-2.98	
Cancer-related financial stress 1 financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001	Financial impact variables					
financial stress better since diagnosis 1 10.0 0.48 0.06-3.87 <0.001	Cancer-related financial stress ¹					
no change4818.81-financial stress worse since diagnosis71 37.8 2.61 $1.70-4.03$ Cancer-related financial strain 2 financial strain better since diagnosis8 14.0 0.55 $0.25-1.24$ 0.003 no change50 22.8 1-financial strain worse since diagnosis62 34.3 1.76 $1.13-2.73$ Cancer-related financial impactneither stress nor strain worse44 19.2 1-either stress or strain worse18 23.7 1.30 $0.70-2.43$ both stress and strain worse57 39.0 2.69 $1.69-4.30$	financial stress better since diagnosis	1	10.0	0.48	0.06-3.87	<0.001
financial stress worse since diagnosis 71 37.8 2.61 1.70-4.03 Cancer-related financial strain ² inancial strain better since diagnosis 8 14.0 0.55 0.25-1.24 0.003 no change 50 22.8 1 - 1.13-2.73 financial strain worse since diagnosis 62 34.3 1.76 1.13-2.73 Cancer-related financial impact - <0.001	no change	48	18.8	1	-	
Cancer-related financial strain 2 financial strain better since diagnosis814.00.550.25-1.240.003no change5022.81-financial strain worse since diagnosis6234.31.761.13-2.73Cancer-related financial impactneither stress nor strain worse4419.21-<0.001	financial stress worse since diagnosis	71	37.8	2.61	1.70-4.03	
financial strain better since diagnosis 8 14.0 0.55 0.25-1.24 0.003 no change 50 22.8 1 - financial strain worse since diagnosis 62 34.3 1.76 1.13-2.73 Cancer-related financial impact neither stress nor strain worse 44 19.2 1 - <0.001	Cancer-related financial strain ²					
no change5022.81-financial strain worse since diagnosis6234.31.761.13-2.73Cancer-related financial impact4419.21-<0.001either stress nor strain worse4419.21-<0.001	financial strain better since diagnosis	8	14.0	0.55	0.25-1.24	0.003
financial strain worse since diagnosis6234.31.761.13-2.73Cancer-related financial impact-<0.001neither stress nor strain worse4419.21-<0.001	no change	50	22.8	1	-	_
Cancer-related financial impact4419.21-<0.001either stress or strain worse1823.71.300.70-2.43both stress and strain worse5739.02.691.69-4.30	financial strain worse since diagnosis	62	34.3	1.76	1.13-2.73	
neither stress nor strain worse 44 19.2 1 - <0.001 either stress or strain worse 18 23.7 1.30 0.70-2.43 both stress and strain worse 57 39.0 2.69 1.69-4.30	Cancer-related financial impact					
either stress or strain worse1823.71.300.70-2.43both stress and strain worse5739.02.691.69-4.30	neither stress nor strain worse	44	19.2	1	-	<0.001
both stress and strain worse 57 39.0 2.69 1.69-4.30	either stress or strain worse	18	23.7	1.30	0.70-2.43	
	both stress and strain worse	57	39.0	2.69	1.69-4.30	

¹ impact of cancer diagnosis on household's ability to make ends meet

² feelings about household financial situation since cancer diagnosis

	Mean	sd	р
Cancer-related financial stress ¹			
financial stress better since diagnosis	81.7	19.6	<0.001
no change	74.8	19.8	
financial stress worse since diagnosis	61.9	22.0	
Cancer-related financial strain ²			
financial strain better since diagnosis	74.9	22.9	<0.001
no change	73.1	20.6	
financial strain worse since diagnosis	63.9	21.2	
Cancer-related financial impact			
neither stress nor strain worse	75.2	20.2	<0.001
either stress or strain worse	68.1	21.0	
both stress and strain worse	61.6	21.6	

Supplementary Table 2: HRQoL scores by cancer-related financial impact: means, standard deviations (sd) and p values from analysis of variance F test

¹ impact of cancer diagnosis on household's ability to make ends meet

² feelings about household financial situation since cancer diagnosis

Supplementary Table 3. Sensitivity analysis - linear regression: associations between cancer-related financial impact and HRQoL, adjusted for demographic, socio-economic and clinical variables: coefficients, standard errors, 95% confidence intervals (CI) and p values

	Coefficient ¹	95% CI	p
Cancer-related financial stress ²			
financial stress better since diagnosis	-12.04	-15.98 to -8.09	<0.001
no change	ref	-	
financial stress worse since diagnosis	7.02	-5.99 to 20.03	
Cancer-related financial strain ³			
financial strain better since diagnosis	-8.61	-12.76 to -4.47	0.009
no change	ref	-	
financial strain worse since diagnosis	0.85	-5.32 to 7.01	
Cancer-related financial impact			
neither stress nor strain worse	ref	-	<0.001
either stress or strain worse	-7.46	-12.86 to -2.06	
both stress and strain worse	-12.66	-17.01 to -8.32	

¹ adjusted for having children, highest level of education completed, receipt of chemotherapy and current stoma

² impact of cancer diagnosis on household's ability to make ends meet

³ feelings about household financial situation since cancer diagnosis



Video Abstract

Click here to access/download Video Abstract 20170308162931_2.mp4